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Gaucher disease (GD), caused by a defect of β-glucosidase (β-Glu), is the most common form of sphingolipidosis. We have previously shown
that a carbohydrate mimic N-octyl-β-valienamine (NOV), an inhibitor of β-Glu, could increase the protein level and enzyme activity of F213I
mutant β-Glu in cultured GD fibroblasts, suggesting that NOVacted as a pharmacological chaperone to accelerate transport and maturation of this
mutant enzyme. In the current study, NOV effects were evaluated in GD fibroblasts with various β-Glu mutations and in COS cells transiently
expressing recombinant mutant proteins. In addition to F213I, NOV was effective on N188S, G202R and N370S mutant forms of β-Glu, whereas
it was ineffective on G193W, D409H and L444P mutants. When expressed in COS cells, the mutant proteins as well as the wild-type protein were
localized predominantly in the endoplasmic reticulum and were sensitive to Endo-H treatment. NOV did not alter this localization or Endo-H
sensitivity, suggesting that it acted in the endoplasmic reticulum. Profiling of N-alkyl-β-valienamines with various lengths of the acyl chain
showed that N-dodecyl-β-valienamine was as effective as NOV. These results suggest a potential therapeutic value of NOV and related
compounds for GD with a broad range of β-Glu mutations.
© 2007 Elsevier B.V. All rights reserved.Keywords: Gaucher disease; β-glucosidase; Valienamine; Chaperone1. Introduction
Gaucher disease (GD) is an inherited lipid storage disorder
characterized by lysosomal accumulation of glucocerebroside
(glucosylceramide) in monocyte-macrophage cells [1]. It is
caused by mutations in a gene that encodes acid β-glucosidase
(β-Glu; glucocerebrosidase EC3.2.1.45). Patients with GDAbbreviations: β-Glu, β-glucosidase; NOV, N-octyl-β-valienamine;
ER, endoplasmic reticulum; GD, Gaucher disease; NN-DNJ, N-nonyl-
deoxy-nojirimaycin
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doi:10.1016/j.bbadis.2007.02.003exhibit visceral symptoms such as hepatosplenomegaly,
anemia, bone lesions and respiratory failure, with or without
progressive neurological symptoms. Patients without neurolo-
gical symptoms are classified as type 1, whereas those with
neurological symptoms are classified into type 2 (acute infantile
form) and type 3 (juvenile form).
At present, there are two established therapeutic strategies for
GD: enzyme replacement therapy and substrate reduction
therapy. Enzyme replacement has been achieved by intravenous
administration of macrophage-targeted recombinant β-Glu [2]
whereas substrate reduction has been achieved by oral
administration of N-butyl-deoxynojirimycin (OGT918), which
inhibits glucosyltransferase and decreases substrate biosynthesis
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hematologic and skeletal abnormalities [4–6]. Unfortunately,
the efficacy of these therapies to neurological manifestations is,
if any, limited [7–10].
It has been known that some of the disease-causing
mutations of β-Glu do not interfere with its catalytic activity
but disrupt either its proper folding in the endoplasmic
reticulum (ER) or intracellular trafficking out of this compart-
ment. Recent evidence suggested that the mutant proteins,
retained in the ER because of improper folding or trafficking,
were degraded by the proteasome in a series of processes
summarized as ERAD (ER-associated protein degradation)
[11,12]. This bases the idea of “enzyme enhancement ther-
apy”, a novel therapeutic strategy for GD, which aims at sta-
bilization and rescue of the mutant enzyme by using cell-
permeable small molecules [13,14]. In pursuit of this idea, we
have shown that a carbohydrate mimic N-octyl-β-valienamine
(NOV), an inhibitor of β-Glu, could increase the protein level
and enzyme activity of F213I mutant β-Glu in cultured GD
fibroblasts [15], whereas Sawkar and colleagues reported that
N-nonyl-deoxynojirimaycin (NN-DNJ), another inhibitor of
β-Glu, could increase the enzyme activity of N370S and
G202R mutants [16,17]. In a recent review by Bernier et al.
[18], the term “chemical chaperone” was used to describe
molecules that help folding of proteins in a nonspecific
manner, whereas those with specific effects on the target
protein were termed “pharmacological chaperone”. In addi-
tion, the term “enzyme enhancement activity (EEA)” is de-
fined as an activity of a molecule to increase the cellular
enzyme activity when the molecule is applied to live cells
[14].
The purpose of the current study was to further explore the
potential of NOV as a pharmacological chaperone for β-Glu
mutant proteins. For this purpose, we examined EEA of NOV in
cultured human GD fibroblasts as well as in COS cells
transiently expressing recombinant mutant proteins. Since we
found that NOV was effective on both N370S and G202R
mutants, we compared EEA of NOV and that of NN-DNJ. We
also tested activities of N-alkyl-β-valienamines with various
lengths of the acyl chain on the F213I mutant.
2. Materials and methods
2.1. Materials
Dulbecco's Modified Eagle's Medium (DMEM), bovine calf serum (BCS)
and LipofactAMINE reagent were obtained from Life Technologies Inc. N-
alkyl-β-valienamine hydrochlorides were synthesized in our laboratory (Central
Research Laboratories, Seikagaku Co.). Stock solution of the compounds was
prepared in H2O at 3 mM and stored at −20 °C. Anti-Flag M2 affinity gel and
rabbit polyclonal anti-Flag antibody were from Sigma. Endoglycosidase-H was
from New England Biolabs.
2.2. Construction of β-Glu expression plasmids
Human β-Glu cDNA (a kind gift from Dr. S. Tsuji, Tokyo University) was
subcloned into a mammalian expression vector pCAGGS. A Flag-epitope was
introduced to the C-terminus of the cDNA by PCR. The following mutations
were introduced by using the Quick Change site-directed mutagenesis kit:N188S, G193W, G202R, F213I, N370S and L444P. All the mutations were
confirmed by direct sequencing.
2.3. Cell culture
Human skin fibroblasts and COS cells were cultured in DMEM/10% BCS at
37 °C in 5% CO2. We used one control cell line (H8) and 9 lines of GD cells. 6
lines of GD cells were from Japanese patients. 4 cell lines carried β-Glu
mutations of F213I/F213I, G202R/L444P, N188S/G193W and nt1447de-
l20insTG/L444P, whereas in the other 2 cell lines, only one β-Glu mutation,
nt1447del20insTG or D409H, was identified and the mutation on the other allele
was left unknown [19]. The other 3 lines of GD cells that carried the N370S
mutation were from Caucasian patients: two cell lines (DMN00.41 and
DMN87.30) carried N370S homozygous mutations and one cell line carried
N370S/84GG. Both 84GG and nt1447del20insTG are predicted to cause
premature termination of the encoded protein. Culture medium was replaced
every 2 days with fresh media supplemented with or without N-alkyl-β-
valienamines at the indicated concentrations. COS cells in 35-mm dishes were
transfected with β-Glu cDNA by using LipofactAMINE according to
manufacturer's instructions. 24 h post-transfection, cells were treated with or
without the compounds for 24 h.
2.4. Immunoprecipitation and immunoblotting
All procedures were carried out at 4 °C. COS cells were lysed by sonication
in PBS supplemented with 1% Triton X-100 and a protease inhibitor cocktail
(Boehringer). After a brief centrifugation to remove insoluble material, the
supernatant was precleared with an aliquot of agarose beads. For immunopre-
cipitation of Flag-β-Glu, the lysates (500 μl from a 35-mm dish) were incubated
for 16 h with anti-Flag M2 agarose beads (20 μl of 50% slurry). The beads were
washed with PBS/1% Triton X-100, rinsed with H2O and the final volume of the
precipitates was adjusted to 40 μl with H2O. For the enzyme assay, 4 μl of the
precipitates was used as described below. For immunoblotting, bound proteins
were eluted by incubation of 20 μl of precipitates with the same volume of 2×
SDS-PAGE sample buffer at 100 °C for 3 min. SDS-PAGE and Western transfer
were carried out as previously described [15]. The blots were probed with rabbit
polyclonal anti-Flag antibody and developed using an ECL kit (Amersham
Pharmacia).
2.5. In vitro enzyme assay
β-Glu activities in cell lysates or immunoprecipitates were determined by
using 4-methylumbelliferone-conjugated β-D-glucopyranoside as a substrate
[20]. For preparation of cell lysates, cells in 35-mm dishes were scraped into
100 μl of ice-cold H2O and lysed by sonication. Insoluble materials were
removed by centrifugation and protein concentrations were determined with a
BCA microprotein assay kit. Anti-Flag immunoprecipitates were prepared as
described above. 4 μl of the lysates or immunoprecipitates was incubated at
37 °C with 8 μl of the substrate solution in 0.1 M citrate buffer, pH 5.2,
supplemented with sodium taurocholate (0.8% w/v). The reaction was
terminated by adding 0.4 ml of 0.2 M glycine sodium hydroxide buffer (pH
10.7). Liberated 4-methylumbelliferone was measured with Perkin Elmer
Luminescence Spectrometer (excitation wave length: 340 nm; emission:
460 nm). One unit of enzyme activity was defined as nmol of 4-
methylumbelliferone released per hour and normalized for the amount of
protein contained in the lysates.
2.6. Intact cell enzyme assay
β-Glu activities in live cells were estimated by the methods described by
Sawkar et al. [16]. Briefly, cells in 24-well plates were treated with NOVor NN-
DNJ for 4 days. After washing with PBS, the cells were incubated in 80 μl of
PBS and 80 μl of 0.2 M acetate buffer (pH 4.0). The reaction was started by
addition of 100 μl of 4-methylumbelliferyl-β-D-glucoside (5 mM), followed by
incubation at 37 °C for 1 h. The reaction was stopped by lysing the cells by the
addition of 2 ml of 0.2 M glycine buffer (pH 10.7) and liberated 4-
methylumbelliferone was quantified. Every experiment was performed in
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epoxide (CBE: Toronto Research Chemicals) at 0.5 mM for 1 h. The CBE-
sensitive component was ascribed to lysosomal β-Glu, whereas the CBE-
insensitive component was ascribed to non-lysosomal β-Glu.
2.7. Endoglycosidase-H treatment
Cell lysates (in H2O containing ∼40 μg protein) from transfected COS cells
were incubated at 100 °C for 10 min with 0.5% SDS and 40 mM DTT to
denature proteins. They were then incubated at 37 °C for 1 h with 0.5 unit of
endoglycosidase-H (Endo-H) in 50 mM citrate buffer (pH 5.5). The reaction
mixture was subjected to SDS-PAGE, Western transfer and anti-Flag
immunoblotting as described above.
2.8. Immunofluorescence
We used staining procedures described previously [15]. Briefly, COS cells
grown on cover glasses were transfected with Flag-β-Glu cDNA and 24 h post-
transfection, exposed to Lysotracker Red (0.5 μM; Molecular Probe) for 1 h.
Cells were fixed with 4% paraformaldehyde and permeabilized with 1%
TritonX-100. They were incubated with rabbit polyclonal anti-Flag antibody
(1:500), followed by Alexa488-conjugated anti-rabbit IgG. Fluorescent images
were collected by using a Leica TSC SP2 confocal laser microscope.
3. Results
3.1. EEA of NOV in human GD fibroblasts assessed by ex vivo
enzyme assay
In our previous study [15], EEA of NOV was evaluated by
ex vivo experiments in which GD cells were treated with NOV
for 4 days followed by determination of the enzyme activity in
cell lysates. By this method, we found significant EEA of NOV
in F213I homozygous and heterozygous (F213I/L444P) cells.
The maximum response was obtained at an NOV concentration
of 30 μM in F213I homozygous cells. NOV was ineffective in
cells with mutations of N370S/84GG, L444P/L444P and
L444P/RecNcil.
N-alkyl-β-valienamine preparations, including NOV, used in
our previous study were poorly soluble in water, and hence in
culture medium. Although NOV had the best solubility among
theN-alkyl-β-valienamines, it was barely soluble in water above
3 mM. To test whether the water-solubility affected EEA, we
prepared hydrochloride forms of N-alkyl-β-valienamines (see
Fig. 4a), which were easily soluble in water above 30 mM. By
using the hydrochloride form of NOV, we could reproduce EEA
of NOV in F213I homozygous cells but with a different dose–
response profile: the maximum response was obtained at 3 μM
(Fig. 1a). Because of this improved efficacy, hydrochloride
preparations were used in all the subsequent experiments.
In the 7 lines of GD cells newly included in the screening, we
found statistically significant EEA of NOV in four lines of cells
with mutations of N188S/G193W, G202R/L444P and N370S/
N370S. NOV effects on the two cell lines with N370
homozygous mutations were remarkably similar to each other,
causing an∼2-fold increase at concentration of 3 and 30 μM. In
accordance with the results in our previous study [15], NOV
elicited weak EEA in N370S/84GG cells, although the increase
was not statistically significant. In contrast, NOV elicited no
effects in cells with mutations of nt1447del20insTG/L444P. Intwo cell lines, only one mutation of β-Glu, D409H or
nt1447del20insTG, was identified, and the mutation on the
other allele was left unknown. NOV effects were also negative
in these two lines of cells (Fig. 1a).
3.2. EEA of NOV and NN-DNJ assessed by intact cell enzyme
assay
The above ex vivo enzyme assay did not indicate whether the
lysosomal enzyme activity was enhanced by NOV. To
compensate for this, we employed “intact cell enzyme assay”
described by Sawkar et al. [16], in which the cellular enzyme
activity was estimated by application of the substrate (4-
methylumbelliferone-conjugatedβ-D-glucopyranoside) to intact
cells followed by quantification of liberated 4-methylumbelli-
ferone. In this assay, cells were pretreated with or without a high
concentration (0.5 mM) of conduritol B epoxide (CBE), an
irreversible inhibitor of lysosomal β-Glu, before exposure to the
substrate. In wild-type cells, more than 95% of the total cellular
enzyme activity was sensitive to CBE, suggesting that the
degradation was mostly due to lysosomal enzyme activity. There
were no significant differences in the absolute values of the
CBE-insensitive activity (i.e., non-lysosomal enzyme activity)
between control and GD cells (data not shown).
In accordance with the results of ex vivo enzyme assay, NOV
was effective in cells with mutations of F213I/F213I, N188S/
G193W, G202R/L444P and N370S/N370S, but not in cells with
mutations of L444P/RecNcil, L444P/L444P and D409H/
unknown (Fig. 1b). In contrast to the results of ex vivo enzyme
assay, however, NOVwas clearly effective onN370S/84GG cells.
We also evaluated EEA of NN-DNJ and found significant effects
of this compound in cells with mutations of N370S/N370S and
N370S/84GG. This result was in accordance with the report by
Sawkar et al. [17] who found EEA of NN-DNJ in cells with
homozygous mutations of N370S and G202R. NN-DNJ was also
effective in cells with mutations of F213I/F213I. Although the
increases were not statistically significant, NN-DNJ elicited weak
EEA in cells with mutations of N188S/G193W and G202R/
L444P, whereas it was not at all effective in cells withmutations of
L444P/RecNcil, L444P/L444P and D409H/unknown. Thus, it
appeared that the two compounds, NOVand NN-DNJ, shared the
same selectivity on β-Glu mutations. In addition, neither NOV
nor NN-DNJ affected the levels of CBE-insensitive, non-
lysosomal enzyme activity (data not shown).
Given the similar effects of NOVand NN-DNJ, we examined
whether these two compounds acted synergistically or not.
When F213I/F213I cells were exposed to NOV and NN-DNJ
(both at 3 μM) simultaneously, the effects were not additive, but
EEA of NOV was rather diminished (Fig. 1b). Similar findings
were reproduced in N188S/G193W and G202R/L444P cells. In
two lines of N370 homozygous cells and N370S/84GG cells,
NN-DNJ did not reduce EEA of NOV, but again the effects of
these two compounds were not additive. To further confirm this
lack of co-operation, we evaluated in vitro inhibitory activity of
NN-DNJ in the presence or absence of NOV and found that
NOV caused a dose-dependent decrease in the efficacy of NN-
DNJ (Fig. 1c). The IC50 values for NN-DNJ were 0.31±0.03
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presence of NOV (3 μM), respectively. This NOVeffect was not
specific for NN-DNJ but a similar decrease in the inhibitory
activity was also observed for CBE. As a negative control, N-
butyl-β-valienamine, which has a very weak in vitro inhibitory
activity (see Fig. 4), failed to affect the activities of NN-DNJ
and CBE.Fig. 1. EEA of NOVand NN-DNJ on mutant β-Glu in GD fibroblasts. (a) Ex vivo enz
of increasing concentrations of NOVand β-Glu activity in cell lysates was determine
panel whereas those with negative responses were shown in the lower panel. Each p
marks indicate that the values are statistically different from the values in the absence
for 4 days in the absence or presence of NOV and/or NN-DNJ (both at 3 μM). Lyso
methods. Each bar represents the mean±SEM of 3 determinations each done in tr
drug (t test). (c) Effects of NOV on in vitro inhibitory activities of NN-DNJ and C
control cells were determined in the absence or presence of NOV (upper panels). A
(lower panels). Each point represents the mean of duplicates obtained in a single3.3. EEA of NOV on recombinant mutant β-Glu expressed in
COS cells
Primary-cultured human cells have several disadvantages for
evaluation of EEA, including their genetic heterogeneity and
heterozygosity of the mutations. For example, we could not tell
from the positive effect of NOV in N188S/G193W cells whichyme assay. 9 lines of GD cells were cultured for 4 days in the absence or presence
d. The data from cells with positive responses to NOV were shown in the upper
oint represents the mean±SEM of 3 determinations each done in triplicate. Red
of the drug (⁎p<0.05, t test). (b) Intact cell enzyme assay. GD cells were cultured
somal β-Glu activity was estimated in intact cells as described in Materials and
iplicate. ⁎p<0.05, statistically different from the values in the absence of the
BE. Inhibitory activities of NN-DNJ and CBE against β-Glu in lysates from a
s a control, the same experiments were repeated with N-butyl-β-valienamine
experiment. Similar results were reproduced twice.
Fig. 1 (continued).
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alternative method to evaluate EEA, we used heterologous
expression of recombinant β-Glu in COS cells. A problem with
this system was the endogenous β-Glu activity of COS cells. To
circumvent this problem, we placed a Flag-epitope at the C-
terminus of recombinant β-Glu and determined the enzyme
activity recovered in anti-Flag immunoprecipitates. Practically,
24 h after transfection, the cells were exposed to NOV for
another 24 h, and cell lysates were subjected to anti-Flag M2
immunoprecipitation. As shown in Fig. 2a, the immunopreci-
pitates from mock-transfected cells contained virtually no
activity whereas those from cells transfected with mutant
Flag-β-Glu contained various levels of activities. The relative
levels of the activities in immunoprecipitates (Fig. 2a, right
panel) faithfully reflected the relative levels in lysates (left
panel), suggesting similar efficacies of immunoprecipitation
between the different constructs.
By using this immunoprecipitation/enzyme assay, we
evaluated EEA of NOV on the wild-type and 6 kinds of β-
Glu mutants and found dose-dependent, positive effects on
N188S, G202R, F213I and N370S mutants, and negative
effects on G193W and L444P mutants (Fig. 2b). The profiles
of dose-dependence were different from those in human cells:
with the exception of N188S, the maximum effects of NOV
were obtained at 10 μM, the highest concentration applied.
The effect on the wild-type β-Glu was negative. EEA of
NOV on the 4 kinds of mutants were statistically significant
as analyzed using the data at an NOV concentration of 10 μM
(Fig. 2c). Anti-Flag Western blotting of immunoprecipitation
products showed that NOV caused dose-dependent increases
in the protein levels of N188S, G202R and F213I mutants.The protein levels of N370S mutant was marginally increased
by NOV, whereas the levels of G193W and L444P mutants
were not at all affected (Fig. 2b).
3.4. Intracellular localization and processing of recombinant
β-Glu expressed in COS cells
In our previous study using F213I homozygous human cells
[15], we could show by immunofluorescence and cell
fractionation experiments that NOV restored lysosomal locali-
zation of the mutant β-Glu. Having shown EEA of NOVon the
recombinant proteins expressed in COS cells, we examined
whether there were any differences in the intracellular
localization and processing of the proteins between the wild-
type and mutants, and whether NOV caused any alterations.
Anti-Flag immunofluorescence of the wild-type Flag-β-Glu
showed reticular distribution throughout the cytosol, indicating
its predominant localization in the ER. The anti-Flag signals
showed little co-localization with Lysotracker red (Fig. 3a,
upper panels). This distribution was in contrast to lysosomal
localization of the endogenous, wild-type β-Glu in human
fibroblasts [15], but was not specific to COS cells. Similar
intracellular distribution was reproduced in CHO, HeLa and
HEK293 cells (data not shown). This distribution was neither
specific for the Flag-tagged protein because similar distribution
was observed for recombinant proteins tagged with a myc-
epitope or GFP (data not shown).
Like the wild-type protein, F213I mutant Flag-β-Glu (Fig.
3a, middle panels) as well as other mutant proteins (data not
shown) were mainly localized in the ER and did not co-
localize with Lysotracker red. To confirm this localization, we
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(Fig. 3b). Anti-Flag Western blotting of the wild-type Flag-β-
Glu gave two bands: the major band at 66 kDa and the minor
band at 62 kDa, which represented the immature ER form andthe mature post-Golgi form, respectively [11]. As expected,
Endo-H digestion abolished the 66 kDa band and yielded a
band at 58 kDa, which corresponds to the non-glycosylated
protein, whereas it barely affected the 62 kDa band. The same
593K. Lei et al. / Biochimica et Biophysica Acta 1772 (2007) 587–596experiments on mutant proteins revealed similar results,
confirming predominant localization in the ER of both wild-
type and mutant proteins in COS cells.
NOV treatment of transfected cells failed to alter the
intracellular distribution and processing of expressed proteins,
as assessed by anti-Flag immunofluorescence (Fig. 3a, lower
panels) and Endo-H digestion (Fig. 3b). These findings
suggested that the site of action of NOV was the ER, consistent
with our assumption that it acted as a pharmacological
chaperone to protect mutant proteins from ERAD. However,
these results also indicated that the heterologous expression was
inappropriate as an experimental system to assess lysosomal
transport of rescued proteins.
3.5. EEA of N-alkyl-valienamines related to NOV
All of the pharmacological chaperones for mutant lysosomal
enzymes described so far are inhibitors of the target enzyme
[21]. The hypothesis “the best chaperone is the best inhibitor”
postulates that the activity of a molecule as a chaperone
depends on its binding affinity to the target enzyme, and hence
on its inhibitory activity [22]. We have shown previously that
the in vitro inhibitory activity of N-alkyl-β-valienamines
against β-Glu depended on the number and the length of the
acyl chain [23,24]. To examine whether the above hypothesis
holds true for N-alkyl-β-valienamines, we prepared com-
pounds with various lengths of the acyl chain and compared
their in vitro inhibitory activities and EEA. Compounds a–e
listed in Fig. 4a contained a single acyl chain with various
lengths, whereas compound f contained double acyl chains.
Compound g carried a glucopyranosyl head group instead of a
valienamine head group, and was included as a negative
control.
In vitro inhibition experiments using cell lysates from
control human fibroblasts revealed that compound f with
double acyl chains was the best β-Glu inhibitor among these
compounds, with the following rank order of potency: f>b,
e>c, d>a, g (Fig. 4b, and the IC50 values were given in Fig.
4a). Immunoprecipitation/enzyme assays using COS cells
transfected with F213I mutant Flag-β-Glu showed that
compound c (N-dodecacyl-β-valienamine) exhibited EEA,
which was as potent as that of compound b (NOV).
Compound d exhibited week EEA, whereas compounds e
and f rather suppressed the enzyme activity. Compounds a
and g, both of which had a weak in vitro inhibitory activity,
failed to alter the enzyme activity of the F213I mutant (Fig.
4c, and the relative efficacies were summarized in Fig. 4a).
These findings indicated that the simple “the best chaperoneFig. 2. Effects of NOVon recombinant β-Glu expressed in COS cells. COS cells were
treated with or without NOV for 24 h. (a) Basal activities of β-Glu in cell lysates
activities were expressed as relative to that of the wild-type protein (100%). The valu
12 nmol/mg protein/h (means±SEM, n=3), respectively. (b, c) Effects of NOVon p
cells were treated with or without increasing concentrations of NOV and the IP pro
described in Materials and methods. Molecular weights are given on the left (kDa). Th
for comparison of NOV effects on individual mutants. All in a–c, each bar or poin
different from the values in the absence of the drug (t test).is the best inhibitor” hypothesis did not hold true for N-alkyl-
β-valienamines, and suggested that the presence of a single acyl
chain with an appropriate length (i.e., carbon numbers between 8
and 14) was necessary for them to act as a chaperone for mutant
β-Glu.
4. Discussion
In the current study, we evaluated EEA of NOVin human GD
cells using two assays: ex vivo enzyme assay (Fig. 1a) and intact
cell enzyme assay (Fig. 1b). With the exception of N370S/84GG
cells, these two assays gave the same results: NOV exhibited
EEA in 5 GD cell lines with mutations of F213I/F213I, N188S/
G193W, G202R/L444P and N370S/N370S, whereas it was
ineffective in cells with mutations of L444P/L444P, L444P/
RecNciI and D409H/unknown. It was also ineffective in cells
with mutations of nt1447del20insTG/L444P and nt1447de-
l20insTG/unknown, in ex vivo enzyme assay. NOV was only
marginally effective in N370S/84GG cells as assessed by ex
vivo enzyme assay whereas it caused clear EEA in the same cells
as assessed by intact cell enzyme assay. The precise reason for
this discrepancy was left unknown, but it may suggest that intact
cell enzyme assay was more sensitive than ex vivo enzyme assay
to detect EEA.
Using heterologous expression of recombinant Flag-tagged
β-Glu in COS cells, we could further confirm EEA of NOV
(Fig. 2). It was effective on N188S, G202R, F213I and N370S
mutants but was ineffective on G193W and L444P mutants.
These results confirmed the selective effects of NOV on
individual mutants as expected from its effects in human cells.
Besides, this analysis suggested that EEA of NOV on N188S/
G193W human cells reflected its selective effect on N188S
mutant. Anti-Flag Western blotting showed that NOV-induced
increase in the enzyme activity was accompanied by increased
protein levels of the mutant proteins, consistent with an action
of NOV as a pharmacological chaperone. The identical genetic
background of this heterologous expression system is a clear
advantage over human cells to assess EEA. However, it also had
a disadvantage that, unlike the endogenous protein, the
expressed protein was retained in the ER (Fig. 3) and hence
the lysosomal transport of rescued protein could not be
assessed. Nonetheless, the heterologous expression system
will be a useful alternative to evaluate EEA when human cells
with specific mutations are not available.
Studies on genotype–phenotype relationships in human
patients have shown that except for the N370S mutation, which
is exclusively associated with type I, non-neuronopathic form,
the other three mutations with positive responses to NOVtransfected with Flag-tagged β-Glu constructs. 24 h post-transfection, cells were
(left panel) and anti-Flag immunoprecipitation (IP) products (right panel). The
es for the wild-type protein in lysates and IP products were 132±16 and 310±
rotein levels and activities of recombinant β-Glu in anti-Flag IP products. In b,
ducts were subjected to in vitro enzyme assay or anti-Flag immunoblotting as
e data with NOV concentrations at 0 and 10 μMwere depicted in a bar graph in c
t represents mean±SEM of more than 3 determinations. ⁎p<0.05, statistically
Fig. 3. Intracellular localization and processing of recombinant β-Glu expressed in COS cells. (a) Immunofluorescence. Cells were transfected with wild-type Flag-β-
Glu (upper panels) or F213I mutant. Cells transfected with F213I mutant were cultured for 24 h in the absence (middle panels) or presence (lower panels) of NOV
(10 μM). They were exposed to Lysotracker red before fixation and stained with anti-Flag antibody. Bound antibody was visualized with Alexa488-conjugated
secondary antibody. Shown are the images obtained with a confocal microscope. (b) Endo-H sensitivity. Lysates from cells transfected with each Flag-β-Glu construct
were subjected to Endo-H digestion followed by SDS-PAGE and anti-Flag immunoblotting (upper panel). Cells transfected with wild-type Flag-β-Glu or F213I
mutant were treated with or without NOV (lower panel). Molecular weights are given on the left (kDa). All results shown were representative and were reproduced at
least twice.
594 K. Lei et al. / Biochimica et Biophysica Acta 1772 (2007) 587–596(N188S, G202R, F213I), can be associated with type 2 or 3,
neuronopathic forms [19,25].
Recently, X-ray crystallography of human β-Glu revealed
that it consisted of three structural domains [26]. Domain III
contains the catalytic site, whereas the functional significance of
domains I and II is left unknown. All the mutations with positiveresponses to NOV (N188S, G202R, F213I and N370S) were
located in domain III, whereas those with negative responses,
L444P and D409Hwere located in domain II and I, respectively.
Since NOV is a structural mimic of the substrate, it is expected to
bind to domain III. Therefore, localization of the mutations in
domain III might be a prerequisite to pharmacological rescue of
Fig. 4. Profiling of N-alkyl-β-valienamines. (a) Chemical structures of the compounds evaluated in this study. Compounds a–f are N-alkyl-β-valienamines with
different acyl chains. They are all in a hydrochloride form, except for f. Compound g contains a glucopyranosyl head group instead of a valienamine head group. (b) In
vitro inhibition of β-Glu. β-Glu activity in lysates from control human fibroblasts was determined in the absence or presence of increasing concentrations of each
compound. Each point represents the mean of triplicate determinations obtained in a single experiment. IC50 values for individual compounds (means of three
independent determinations) were given in a. (c) EEA on F213I mutant β-Glu expressed in COS cells. Cells transfected with F213I mutant Flag-β-Glu were incubated
in the absence or presence of increasing concentrations of each compound. β-Glu activity of anti-Flag immunoprecipitates was determined as described in Materials
and methods. Values were shown as relative to the values in the absence of any compound. Each point represents the mean±SEM of 3 determinations. ⁎p<0.05,
statistically different from the values in the absence of any compound (t test).
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remains that the selective effects of NOV simply reflected the
degree of instability of individual mutant proteins.
By using intact cell enzyme assay in human GD cells, we
compared effects of NOV and NN-DNJ and found similar
responses of individual cells to the two compounds (Fig. 1b).
This was not surprising, given that NN-DNJ was also a
structural mimic of the substrate and was expected to act in a
manner similar to NOV. An important finding was that these
two compounds did not work synergistically, but simultaneous
addition of the two rather suppressed the action of each
compound. Although the molecular mechanism for this lack of
co-operation was left unknown, suppression of in vitro
inhibitory activity of NN-DNJ by NOV (Fig. 1c) suggested
that the presence of NOV hindered the binding of NN-DNJ to
the enzyme, and vice versa.
We have shown that the optimal concentration of the
hydrochloride form of NOV to elicit EEA on F213I homozygouscells was 10 times lower than that of the non-hydrochloride
form, most likely because of its better solubility in the medium
(Fig. 1a). By profiling the activities of N-alkyl-β-valienamines,
we also found that N-dodecacyl-β-valienamine elicited EEA as
potent as that of NOV (Fig. 4). In addition, NOV appeared to
work better than NN-DNJ at the same concentration, at least in
intact cell enzyme assay using human cells (Fig. 1b). These
findings in cultured cells, however, do not allow us to predict
which compound works best as a pharmacological chaperone in
whole animals, and hence has the best therapeutic value. To
prove the activity of N-octyl-β-epi-valienamine, an isomer of
NOV, as a pharmacological chaperone for mutant β-galactosi-
dase, we developed transgenic mice that lacked the endogenous
wild-type enzyme and instead expressed a mutant human
enzyme [27]. The same strategy will be used to confirm EEA
of NOV and related compounds in whole animals, and to
determine which compound works best as a pharmacological
chaperone for mutant β-Glu.
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